Browse the evidence

Glucagon receptor agonism (GCGRA), particularly in triagonists like retatrutide, increases energy expenditure and enhances weight loss efficacy compared to GLP-1/GIP agonists alone, though it carries risks of adverse events like tachycardia.

Triagonist medications (combining GLP-1, GIP, and Glucagon effects) can achieve higher weight loss (up to 24%) than current GLP-1 drugs by actively increasing how many calories you burn, not just by reducing appetite. While these drugs can cause side effects like rapid heart rate, doctors can manage this by starting with very low doses and increasing them slowly. This approach offers a more sustainable path to weight loss by counteracting the body's tendency to slow down metabolism.

Metabolic surgery (specifically Roux-en-Y Gastric Bypass and Sleeve Gastrectomy) yields significantly higher diabetes remission rates compared to intensive lifestyle interventions or medical therapy alone.

For eligible patients (BMI >= 35, or >= 27 with comorbidities), metabolic surgery (RYGB or Sleeve Gastrectomy) offers the highest chance of type 2 diabetes remission, significantly outperforming lifestyle changes or medication alone. While upfront costs and surgical risks exist, laparoscopic techniques have made it safer, and it reduces long-term healthcare costs by resolving other obesity-related conditions. Early intervention (shorter diabetes duration) improves success rates.

In drug-naive individuals with early type 2 diabetes, sitagliptin treatment (100 mg daily) reduces postprandial glucose excursions regardless of whether the meal is carbohydrate-rich, protein-rich, or lipid-rich.

If you have early type 2 diabetes and take sitagliptin, your blood sugar response to meals is improved regardless of whether you eat carbs, protein, or fat. While protein and fat-rich meals naturally cause smaller blood sugar spikes, the medication helps manage glucose levels across all meal types. This makes dietary flexibility easier, as you don't need to strictly avoid carbohydrates to benefit from the drug's glucose-lowering effects.

Thyroid dysfunction and structural changes caused by overnutrition are largely reversible through weight loss and return to a normal diet.

If you have obesity-related thyroid issues, know that they are likely reversible. Losing weight through diet and lifestyle changes can restore normal thyroid function and hormone levels.

Tirzepatide demonstrates high clinical efficacy but has a higher Incremental Cost-Effectiveness Ratio (ICER), making its cost-effectiveness context-dependent.

Tirzepatide is a highly effective once-weekly peptide for weight loss, but its higher cost-effectiveness ratio means it may not be the most economical choice in all healthcare settings compared to Semaglutide.

Phentermine-topiramate (Qysmia) offers acceptable cost-effectiveness, particularly in low-resource settings, making it a practical alternative to more expensive drugs.

For patients in low-resource settings, Phentermine-topiramate (Qysmia) is a cost-effective and practical alternative to more expensive obesity medications.

Tirzepatide improves cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, reducing heart failure hospitalizations and improving quality of life.

For patients with obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide (15 mg weekly) has been shown to significantly reduce the risk of heart failure hospitalizations and cardiovascular death. It also improves heart structure and quality of life. This makes it a valuable option for this specific population, in addition to its benefits for diabetes and weight loss.

Tirzepatide is the first pharmacologic therapy approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, significantly reducing the Apnea-Hypopnea Index (AHI).

Tirzepatide (Zepbound) is now approved for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. It significantly reduces the number of breathing interruptions per hour (AHI) by 50-60%. This may lead to less daytime sleepiness and potentially reduced reliance on CPAP machines, though long-term data is still emerging.

Multidisciplinary therapy reduces inflammatory biomarkers (CRP, IL-6, TNF-alpha) and improves the leptin/adiponectin ratio in adults with obesity.

Reducing inflammation is a key benefit of weight loss therapy. By losing weight through a multidisciplinary approach, you can lower levels of inflammatory markers like CRP and IL-6, and improve the balance of hormones like leptin and adiponectin, which protects against cardiovascular disease and other complications.

Pharmacological interventions, specifically GLP-1 receptor agonists and SGLT2 inhibitors, reduce epicardial adipose tissue (EAT) volume and improve cardiovascular outcomes, often independent of weight loss.

If you have T2DM, obesity, or heart failure, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs can reduce the fat around your heart and improve your heart's function, sometimes even without significant weight loss.

In patients with Type 2 Diabetes, GLP-1RA use is strongly associated with prior use of insulin and multiple oral antidiabetic agents, indicating their role as intensification therapies for poorly controlled diabetes.

If you have Type 2 Diabetes and are already taking insulin or multiple oral medications, your provider is likely to prescribe a GLP-1RA as an intensification therapy. This is a standard and effective approach for managing blood sugar when other treatments are insufficient.

GLP-1-based therapies, particularly dual GLP-1/GIP agonists like tirzepatide, produce large, clinically meaningful reductions in AHI and cardiometabolic risk in obesity-associated OSA.

If you have obesity-related sleep apnea, ask your doctor about GLP-1/GIP agonists like tirzepatide. These medications can significantly reduce your apnea severity by reducing weight and metabolic load, offering a systemic treatment option.

GLP-1 and GIP/GLP-1 agonists reduce systemic inflammation (hsCRP, IL-6) and improve metabolic parameters (HbA1c, blood pressure, lipids) in obese patients, contributing to overall cardiovascular risk reduction.

If you are obese, ask your doctor about GLP-1 agonists. They can significantly improve your blood pressure, blood sugar, and inflammation levels, reducing your overall risk of heart disease and stroke.

GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.

If you are struggling to lose weight on GLP-1 medications like liraglutide despite strict adherence, ask your doctor about pharmacogenetic testing for GLP1R variants. Your genetic makeup may dictate whether this specific drug is the right fit for you, helping you avoid ineffective treatments and switch to alternatives sooner.

Tirzepatide's dual GIP/GLP-1 receptor agonism provides a synergistic mechanism that enhances weight loss and mitigates gastrointestinal side effects compared to selective GLP-1 agonists.

Tirzepatide works differently than semaglutide by activating both GIP and GLP-1 receptors. This dual action may lead to greater fat loss and potentially fewer stomach side effects.

GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).

Tirzepatide is the first FDA-approved medical therapy for OSA, showing significant improvements in sleep apnea severity (AHI) in patients with obesity. This benefit occurs both in patients using CPAP and those not using it. It offers a new treatment option for those struggling with OSA, potentially reducing the burden of the disease.

Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.

Newer 'triple-agonist' weight loss medications target three different hormonal pathways (GLP-1, GIP, and Glucagon) instead of just one. Clinical trials show these can lead to over 20% body weight loss, which is significantly higher than older single-target drugs. These are currently experimental and not yet widely available for general use.

Lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin are associated with a reduced risk of acute kidney injury compared to control treatments.

If you are taking lixisenatide, high-dose canagliflozin, empagliflozin, or dapagliflozin, you may have a lower risk of acute kidney injury compared to those not on these medications. Continue to follow your doctor's recommendations for kidney function monitoring, as these benefits do not eliminate the need for standard care.

Tirzepatide (10 mg and 15 mg) significantly improves health-related quality of life (HR-QoL) in Japanese adults with obesity disease compared to placebo over 72 weeks.

For Japanese adults with obesity disease, treatment with tirzepatide (10 mg or 15 mg weekly, escalated from 2.5 mg) alongside lifestyle changes significantly improves quality of life, particularly physical function and psychosocial well-being, compared to placebo over 72 weeks.

Metabolic surgery (VSG/RYGB) alters gut hormone profiles by increasing GLP-1 and PYY while decreasing ghrelin, leading to reduced hunger and improved satiety, which aids in sustained weight loss and glucose control.

Surgery biologically reduces your hunger drive (ghrelin) and increases fullness signals (GLP-1/PYY), making it easier to maintain weight loss compared to dieting alone, which often triggers intense hunger.

Low-carbohydrate diets improve cardiovascular risk markers (triglycerides, HDL, blood sugar, inflammation) and reduce 10-year ASCVD risk scores, despite potential increases in LDL-C in lean individuals.

If you are on a low-carbohydrate diet, expect improvements in triglycerides, HDL, and blood sugar. If your LDL-C rises, discuss with your provider whether it correlates with other risk factors, as overall cardiovascular risk may still decrease.

Low-dose empagliflozin (2.5-5 mg) as adjunct therapy to hybrid closed-loop systems improves postprandial glycemic control and reduces insulin requirements in adults with type 1 diabetes, though it increases the risk of hypoglycemia and requires management of side effects like increased urination.

If you have Type 1 Diabetes and use a hybrid closed-loop system but still struggle with post-meal spikes or high insulin doses, low-dose empagliflozin (2.5-5mg) can significantly improve your time in range and reduce insulin needs. Be aware that it may cause more frequent urination and a higher risk of post-meal lows, which you can manage by adjusting your pump settings. The benefit of better control often outweighs the inconvenience of taking one extra pill.

A non-carbohydrate counting (non-CC) meal bolus strategy based on preprandial glucose levels, when used with open-source automated insulin delivery (AID), significantly improves time in range (TIR) and reduces glycemic variability compared to manual open-loop modes in adults with Type 1 Diabetes.

If you have Type 1 Diabetes and find carbohydrate counting stressful or error-prone, consider using an open-source automated insulin delivery system (like AndroidAPS) with a simplified bolus strategy. Instead of counting carbs, you calculate your insulin based on your pre-meal glucose level and your average mealtime insulin needs. This approach can significantly improve your time in range and reduce glycemic variability, especially at night, without increasing the risk of hypoglycemia. It is a viable alternative for those who find traditional carb counting burdensome.

Intensive lifestyle interventions (ILI) involving caloric restriction and physical activity cause a significant increase in 25-hydroxyvitamin D [25(OH)D] and suppress parathyroid hormone (PTH) elevation during the period of maximal weight loss in adults with type 2 diabetes.

If you have type 2 diabetes and are losing weight through diet and exercise, expect your Vitamin D levels to rise and your Parathyroid Hormone (PTH) to decrease, especially in the first year. This is a normal and likely beneficial response to weight loss, though it may normalize over time. Monitor your bone health as weight loss can also lead to bone loss.